imatinib mesylate has been researched along with elacridar in 6 studies
| Studies (imatinib mesylate) | Trials (imatinib mesylate) | Recent Studies (post-2010) (imatinib mesylate) | Studies (elacridar) | Trials (elacridar) | Recent Studies (post-2010) (elacridar) |
|---|---|---|---|---|---|
| 11,477 | 960 | 5,773 | 284 | 8 | 119 |
| Protein | Taxonomy | imatinib mesylate (IC50) | elacridar (IC50) |
|---|---|---|---|
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 0.4427 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 0.2852 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Breedveld, P; Cipriani, G; Pluim, D; Schellens, JH; Schinkel, AH; van Tellingen, O; Wielinga, P | 1 |
| Bihorel, S; Camenisch, G; Lemaire, M; Scherrmann, JM | 2 |
| Beijnen, JH; Buckle, T; Oostendorp, RL; Schellens, JH; van Tellingen, O | 1 |
| Belhassan, F; Gizurarson, S; Hada, N; Netzer, WJ; Wennogle, LP | 1 |
6 other study(ies) available for imatinib mesylate and elacridar
| Article | Year |
|---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in pat
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acridines; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Benzimidazoles; Biological Transport; Brain; Dogs; Drug Synergism; Humans; Imatinib Mesylate; Male; Membranes; Methotrexate; Mice; Mice, Knockout; Neoplasm Proteins; Omeprazole; Pantoprazole; Piperazines; Pyrimidines; Spodoptera; Sulfoxides; Tetrahydroisoquinolines | 2005 |
Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar.
Topics: Acridines; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Blood-Brain Barrier; Brain; Carbon Radioisotopes; Cyclosporins; Dibenzocycloheptenes; Imatinib Mesylate; Male; Mice; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Tetrahydroisoquinolines | 2007 |
Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.
Topics: Acridines; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Biological Transport, Active; Blood-Brain Barrier; Brain; Cyclosporins; Dibenzocycloheptenes; Dose-Response Relationship, Drug; Enzyme Inhibitors; Imatinib Mesylate; Immunosuppressive Agents; Male; Mice; Mice, Knockout; Piperazines; Pyrimidines; Quinolines; Tetrahydroisoquinolines | 2007 |
The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Absorption; Acridines; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Bile; Brain; Drug Combinations; Drug Resistance, Neoplasm; Feces; Female; Imatinib Mesylate; Kidney; Liver; Metabolic Clearance Rate; Mice; Mice, Knockout; Pantoprazole; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Tetrahydroisoquinolines | 2009 |
Nose-to-brain transport of imatinib mesylate: A pharmacokinetic evaluation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acridines; Administration, Intranasal; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Brain; Epinephrine; Female; Imatinib Mesylate; Injections, Intravenous; Male; Mice, Inbred BALB C; Nasal Mucosa; Pantoprazole; Protein Kinase Inhibitors; Tetrahydroisoquinolines | 2017 |